Once-Daily Indacaterol Acetate, Glycopyrronium Bromide, and Mometasone Furoate as a Fixed-Dose Combination in Japanese Patients with Inadequately Controlled Asthma: A Multicenter, 52-Week Safety Study

被引：0
|
作者：
Sagara, H. [1 ]
D'Andrea, P. [2 ]
Tanase, A. [3 ]
Pethe, A. [2 ]
Tanaka, Y. [4 ]
Matsuo, K. [4 ]
Hosoe, M. [3 ]
机构：
[1] Showa Univ, Sch Med, Dept Med, Div Allergol & Resp Med, Tokyo, Japan
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Novartis Pharma AG, Basel, Switzerland
[4] Novarts Pharma KK, Tokyo, Japan
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2020年 / 201卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3012
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Different daily glycemic profiles after switching from once-daily alogliptin plus twice-daily metformin to their once-daily fixed-dose combination in Japanese type 2 diabetic patients
    Takahara, Mitsuyoshi
    Shiraiwa, Toshihiko
    Katakami, Naoto
    Maeno, Yoshifumi
    Yamamoto, Kaoru
    Shiraiwa, Yuka
    Yoshida, Yoko
    Matsuoka, Taka-Aki
    Shimomura, Iichiro
    ENDOCRINE JOURNAL, 2019, 66 (01) : 11 - 17
  • [42] Non-Inferior Improvement in Asthma Quality of Life and Favorable Benefit in Terms of Lung Function and Asthma Control with Inhaled Combination of Indacaterol/Glycopyrronium/Mometasone Furoate Once-Daily Compared with the "Loose" Combination of Salmeterol/Fluticasone Twice-Daily Plus Tiotropium in Patients with Uncontrolled Asthma: Results of the Phase III ARGON Study
    Gessner, C.
    Kornmann, O.
    Maspero, J.
    van Zyl-Smit, R.
    Kruell, M.
    Sojo, A.
    Salina, A.
    Gupta, P.
    Conde, L. G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [43] Indacaterol/Mometasone Furoate Fixed-Dose Combination Improves Lung Function and Decreases Exacerbations Compared with Salmeterol/Fluticasone in Patients with Uncontrolled Asthma: Pooled Analyses of PALLADIUM and IRIDIUM Studies
    Chapman, K. R.
    van Zyl-Smit, R.
    Kerstjens, H. A. M.
    Gessner, C.
    Hosoe, M.
    Tanase, A.
    Pethe, A.
    Shu, X.
    D'Andrea, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [44] Once-daily, single-inhaler indacaterol/mometasone versus twice-daily salmeterol/fluticasone in Asian patients with inadequately controlled asthma: post hoc pooled analysis from PALLADIUM and IRIDIUM studies
    Gon, Yasuhiro
    Ishii, Tsuyoshi
    Lawrence, David
    Nikolaev, Ivan
    Wang, Dong
    Sumi, Kazuya
    Nakamura, Yoichi
    JOURNAL OF ASTHMA, 2022, 59 (08) : 1627 - 1637
  • [45] COST-UTILITY ANALYSIS OF FIXED DOSE COMBINATION (FDC) OF INDACATEROL ACETATE (IND) GLYCOPYRRONIUM BROMIDE (GLY) AND MOMETASONE FUROATE (MF) AS A MAINTENANCE TREATMENT IN ADULT ASTHMA PATIENTS NOT ADEQUATELY CONTROLLED WITH A MAINTENANCE COMBINATION OF A LONG-ACTING BETA2-AGONIST AND A HIGH DOSE OF AN INHALED CORTICOSTEROID WHO EXPERIENCED ONE OR MORE ASTHMA EXACERBATIONS IN THE PREVIOUS YEAR
    Mangia, P. P.
    Pradelli, L.
    Gallo, O.
    Ritrovato, D.
    Gupta, S.
    VALUE IN HEALTH, 2020, 23 : S719 - S719
  • [46] Efficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: A 24-week placebo and active-controlled randomised trial
    Lotvall, Jan
    Bleecker, Eugene R.
    Busse, William W.
    O'Byrne, Paul M.
    Woodcock, Ashley
    Kerwin, Edward M.
    Stone, Sally
    Forth, Richard
    Jacques, Loretta
    Bateman, Eric D.
    RESPIRATORY MEDICINE, 2014, 108 (01) : 41 - 49
  • [47] A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study
    Filozof, C.
    Gautier, J. -F.
    DIABETIC MEDICINE, 2010, 27 (03) : 318 - 326
  • [48] Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD
    Doherty, Dennis E.
    Tashkin, Donald P.
    Kerwin, Edward
    Knorr, Barbara A.
    Shekar, Tulin
    Banerjee, Sibabrata
    Staudinger, Heribert
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2012, 7 : 57 - 71
  • [49] Tolerability of indacaterol, a novel once-daily β2-agonist, in patients with asthma:: a randomized, placebo-controlled, 28-day safety study
    Yang, William H.
    Martinot, Jean Benoit
    Pohunek, Petr
    Beier, Jutta
    Magula, Daniel
    Cameron, Ray
    Owen, Roger
    Higgins, Mark
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2007, 99 (06) : 555 - 561
  • [50] Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study
    Hsieh, Meng-Jer
    Chen, Ning-Hung
    Cheng, Shih-Lung
    Tao, Chi-Wei
    Wei, Yu-Feng
    Wu, Yao-Kuang
    Chan, Ming-Cheng
    Liu, Shih-Feng
    Hsu, Wu-Huei
    Yang, Tsung-Ming
    Lin, Ming-Shian
    Liu, Ching-Lung
    Kuo, Ping-Hung
    Tsai, Ying-Huang
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2022, 17 : 967 - 976
12345